Doctors Note Logo

Published on: 8/18/2026

Understanding Genetic Transmission: How PHEX Gene Mutations Cause Lifelong Phosphate Leaks

PHEX gene mutations cause X-linked hypophosphatemia (XLH), a lifelong condition in which faulty PHEX signaling allows FGF23 to build up and force the kidneys to leak phosphate into the urine instead of reabsorbing it. Inheritance follows an X-linked dominant pattern, so an affected mother has a 50% chance of passing the mutation to each child while an affected father passes it to all daughters and none of his sons, though many cases arise from new mutations with no family history at all. Because phosphate is lost continuously from infancy onward, bones and teeth cannot mineralize properly, resulting in rickets, bowed legs, short stature, bone and joint pain, dental abscesses, and hearing changes that continue into adulthood. Severity varies widely even among relatives carrying the identical mutation, so inheritance alone does not predict how symptoms will present, and there are several important factors to consider before drawing conclusions, all explained below.

If you recognize these patterns in yourself or your child, the fastest way to organize what you are noticing is a free, instant, online symptom check, which turns vague concerns like leg pain, delayed growth, or repeated dental infections into a clear summary you can bring to a doctor, helping you ask about phosphate testing and reach the right specialist sooner rather than after years of uncertainty.

Last reviewed for medical accu

answer background

Explanation

Understanding Genetic Transmission: How PHEX Gene Mutations Cause Lifelong Phosphate Leaks

X-linked hypophosphatemic rickets osteomalacia (XLH) is a genetic condition marked by low phosphate levels that can lead to soft bones, leg deformities in children and bone pain or fractures in adults. At the heart of XLH is a mutation in the PHEX gene, which disrupts how your body handles phosphate—a mineral essential for bone strength. Below, we explain in plain language how PHEX gene mutations are inherited, how they cause ongoing phosphate loss, and what this means for you or a loved one.

1. What Is the PHEX Gene and Why It Matters

  • PHEX stands for “phosphate‐regulating neutral endopeptidase, X-linked.”
  • It is located on the X chromosome, explaining the “X-linked” part of XLH.
  • Normally, the PHEX protein controls levels of a hormone called fibroblast growth factor 23 (FGF23).
  • FGF23 tells the kidneys how much phosphate to keep or excrete.

When PHEX doesn’t work properly, FGF23 levels stay too high. The kidneys then dump too much phosphate into the urine, leaving too little in the blood for healthy bone mineralization.

2. X-Linked Inheritance: Who Gets Affected?

XLH follows an X-linked dominant pattern:

  • Females have two X chromosomes (XX). If one carries the mutation, they usually show signs of XLH.
  • Males have one X and one Y chromosome (XY). If their single X carries the mutation, they will have XLH, often more severely.
  • An affected mother has a 50% chance of passing the altered gene to each child (son or daughter).
  • An affected father will pass the altered X chromosome to all daughters (who will be affected) but none of his sons.

This pattern means XLH often appears in multiple generations, although severity can vary even within the same family.

3. Biochemical Cascade: From PHEX Mutation to Phosphate Leak

  1. PHEX mutation → PHEX protein can’t regulate FGF23 properly.
  2. FGF23 levels remain elevated.
  3. High FGF23 tells kidneys to excrete phosphate and reduce active vitamin D (calcitriol) production.
  4. Reduced calcitriol means less intestinal absorption of dietary phosphate.
  5. Combined kidney loss + poor absorption → chronically low blood phosphate (hypophosphatemia).
  6. Low phosphate impairs bone mineralization → rickets in children, osteomalacia in adults.

Over time, the ongoing phosphate deficit leads to weaker bones that can bend, fracture or cause pain.

4. Clinical Features: Rickets vs. Osteomalacia

Children (Rickets):

  • Soft, bowed legs or knock-knees
  • Slow growth and short stature
  • Delayed walking or waddling gait
  • Dental abscesses and enlarged joints

Adults (Osteomalacia):

  • Bone pain, especially in hips, thighs or lower back
  • Muscle weakness, making walking or climbing stairs harder
  • Stress fractures in weight-bearing bones
  • Fatigue and reduced quality of life

Because the underlying problem is lifelong, symptoms can persist or recur without ongoing management.

5. Making the Diagnosis

A combination of clinical, laboratory and genetic tools is used:

  • Blood tests: low phosphate, normal calcium, high alkaline phosphatase, elevated FGF23.
  • Urine tests: high phosphate excretion.
  • X-rays: signs of rickets in children (widened growth plates, leg deformities) or osteomalacia in adults (Looser’s zones/stress fractures).
  • Genetic testing: confirms PHEX mutation and helps with family planning.

Early diagnosis allows for earlier intervention, which can improve growth in children and reduce bone pain in adults.

6. Treatment Strategies

There is no cure for XLH, but treatments aim to normalize phosphate levels and support bone health:

• Conventional therapy

  • Oral phosphate supplements (several times daily)
  • Active vitamin D analogs (calcitriol or alfacalcidol) to boost absorption
  • Close monitoring of calcium and parathyroid hormone to avoid side effects

• Targeted therapy

  • Burosumab, an antibody against FGF23, helps reduce phosphate loss and improve bone mineralization

• Supportive measures

  • Physical therapy for muscle strength and mobility
  • Orthopedic surgery for severe bone deformities
  • Regular dental check-ups (dental problems are common)

Your doctor will tailor treatment based on age, severity, response and any side effects.

7. Living with XLH: Practical Tips

  • Maintain a balanced diet rich in calcium and phosphorus.
  • Stick to your medication schedule; missing doses can worsen symptoms.
  • Engage in low-impact activities (e.g., swimming) to keep muscles strong without stressing bones.
  • Watch for dental issues—abscesses may occur even without cavities.
  • Coordinate care among an endocrinologist, nephrologist, orthopedist and dentist.

A proactive approach helps you stay as active and comfortable as possible.

8. When to Seek Help

XLH can vary widely from person to person. Be alert to:

  • New or worsening bone pain
  • Noticeable changes in walking or posture
  • Unusual fatigue or muscle weakness
  • Dental pain or abscesses

If any of these occur, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps.

9. Key Takeaways

  • XLH is an X-linked dominant disorder caused by PHEX gene mutations.
  • Mutations lead to uncontrolled FGF23, causing lifelong phosphate leaks through the kidneys.
  • Children develop rickets; adults develop osteomalacia.
  • Diagnosis relies on lab tests, imaging and genetic confirmation.
  • Treatment includes phosphate supplements, vitamin D analogs and, in many cases, burosumab.
  • Close follow-up and a multidisciplinary team approach support the best outcomes.

Genetic counseling may help affected families understand inheritance risks and guide family planning.

Speak to your doctor about any serious symptoms or concerns. Early recognition and treatment can help reduce complications and improve quality of life.

(References)

  • * Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. PMID: 29947083.

  • * Christov M, Jüppner H. Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):685-706. doi: 10.1016/j.beem.2018.06.004. Epub 2018 Jun 18. PMID: 30449549.

  • * Bitzan M, Goodyer PR. Hypophosphatemic Rickets. Pediatr Clin North Am. 2019 Feb;66(1):179-207. doi: 10.1016/j.pcl.2018.09.004. PMID: 30454743.

  • * Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. PMID: 31104833; PMCID: PMC7179969.

  • * Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.

  • * Miller WL, Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. Horm Res Paediatr. 2022;95(6):579-592. doi: 10.1159/000527011. Epub 2022 Nov 29. PMID: 36446330.

  • * Kamenický P, Briot K, Munns CF, Linglart A. X-linked hypophosphataemia. Lancet. 2024 Aug 31;404(10455):887-901. doi: 10.1016/S0140-6736(24)01305-9. Epub 2024 Aug 21. PMID: 39181153.

  • * Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.

  • * Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.

  • * Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.